BOSTON--(BUSINESS WIRE)--Dec. 20, 2018--
Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a
biopharmaceutical company focused on developing and commercializing
medicines to improve the survival and quality of life of cancer
patients, today announced that it has been selected for addition to the
NASDAQ Biotechnology Index® (NASDAQ: NBI). Verastem Oncology’s addition
to the NBI will become effective prior to market open on Monday,
December 24, 2018.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are
classified as either biotechnology or pharmaceutical according to the
Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index
is calculated under a modified capitalization-weighted methodology and
ranked on annual basis. All securities in the NASDAQ Biotechnology Index
are listed on the NASDAQ Global Market or the NASDAQ Global Select
Market and meet minimum market value and share volume requirements among
other criteria.
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology Index (SM) Fund. In addition, options based on the
iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For
more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005019/en/
Source: Verastem, Inc.
Verastem Oncology:
Brian Sullivan
Senior Director,
Corporate Development
+1 781-469-1636
bsullivan@verastem.com
Media:
Jeff
Stoecker
FleishmanHillard
+1 617-692-0509
media@verastem.com
Investors:
Joseph
Rayne
Argot Partners
+1 617-340-6075
joseph@argotpartners.com
